Hiroshi Kono, Hideki Fujii, Shinji Furuya, Michio Hara, Kazuyoshi Hirayama, Yoshihiro Akazawa, Yuuki Nakata, Masato Tsuchiya, Naohiro Hosomura, Chao Sun

Hiroshi Kono, Hideki Fujii, Shinji Furuya, Michio Hara, Kazuyoshi Hirayama, Yoshihiro Akazawa, Yuuki Nakata, Masato Tsuchiya, Naohiro Hosomura, Chao Sun, First Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan

Author contributions: Kono H conducted this experiment; Fujii H organized this experiment; Furuya S collected samples; Hara M collected samples; Hirayama K analyzed the data; Akazawa Y analyzed the data; Nakata Y analyzed the data; Tsuchiya M collected samples; Hosomura N and Sun C collected samples.

Institutional review board statement: This study was reviewed and approved by the University of Yamanashi, Faculty of Medicine IRB (Prof Zentaro Yamagata).

Informed consent statement: All involved persons (subjects or legally authorized representatives) gave their informed consent (written or verbal, as appropriate) prior to study inclusion.

Conflict-of-interest statement: There are no conflicts-of-interest on this study.

Data sharing statement: Participants gave informed consent for data sharing.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Abstract

AIM
To investigate the role of macrophage colony-stimulating factor (M-CSF) in patients with hepatocellular carcinoma (HCC) after surgery.

METHODS
Expression of M-CSF, distribution of M2 macrophages (M\(_2\)s), and angiogenesis were assessed in the liver, including tumors and peritumoral liver tissues. The prognostic power of these factors was assessed. Mouse isolated hepatic M\(_2\)s or monocytes were cultured with media containing M-CSF. The concentration of vascular endothelial growth factor (VEGF) in media was assessed. Furthermore, the role of the M-CSF-matured hepatic M\(_2\)s on proliferation of the vascular endothelial cell (VEC) was investigated.

RESULTS
A strong correlation between the expressions of M-CSF and CD163 was observed in the peritumoral area. Also, groups with high density of M-CSF, CD163 or CD31 showed a significantly shorter time to recurrence (TTR) than low density groups. Multivariate analysis revealed
the expression of M-CSF or hepatic M2Mφs in the peritumoral area as the most crucial factor responsible for shorter TTR. Moreover, the expression of M-CSF and hepatic M2Mφs in the peritumoral area had better predictable power of overall survival. Values of VEGF in culture media were significantly greater in the hepatic Mφs compared with the monocytes. Proliferation of the VEC was greatest in the cells co-cultured with hepatic Mφs when M-CSF was present in media.

CONCLUSION

M-CSF increases hepatocarcinogenesis, most likely by enhancing an angiogenic factor derived from hepatic Mφ and could be a useful target for therapy against HCC.

Key words: M2 macrophage; Vascular endothelial growth factor; Vascular endothelial cell; Monocyte; Angiogenesis

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This study was designed to investigate the role of macrophage colony-stimulating factor (M-CSF) in patients with hepatocellular carcinoma (HCC) after resection. Groups with high density of M-CSF, CD163 or CD31 showed a significantly shorter time to recurrence (TTR) than low density groups. Multivariate analysis revealed the expression of M-CSF or hepatic M2Mφs in the peritumoral area as the most crucial factor responsible for shorter TTR. The expression of M-CSF and hepatic M2Mφs in the peritumoral area had better power for the prediction of overall survival. Thus, M-CSF could be a useful target for therapy against HCC.

INTRODUCTION

Hepatocellular carcinoma (HCC) is a globally common cancer, resulting over one million deaths every year[1]. The etiology of HCC is strongly associated with liver cirrhosis due to alcohol abuse and hepatitis viral infection, exposure to aflatoxin B1 and various metabolic liver diseases[2]. The mechanisms of HCC are mainly still unknown.

Although liver resection improves overall survival in patients with HCC[3], a high rate of postoperative recurrence is still one critical problem, including intrahepatic metastasis (IM) or multicentric (MC) recurrence. Biomarkers, which derived from carcinoma cells or tumor-associated fibrotic tissues, have been studied[4]; however, results have not been well elucidated. Previously, the oncogenesis of HCC has been predominantly investigated in terms of oncogenic factors above mentioned. Alternatively, chronic inflammation is also strongly linked to mechanisms of initiation or progression of carcinoma by increasing production of reactive oxygen species and inflammatory cytokines from inflammatory cells, such as hepatic macrophages (Mφ), “Kupffer cells (KC)”, and infiltrating neutrophils into the liver[5,6].

Previously, we reported a relationship between chronic inflammation caused by hepatitis viral infection and DNA damage due to oxidative stress in patients with HCC. Furthermore, it was also reported that the period of post-operative recurrence was much shorter in patients with high oxidative stress compared with patients who had low oxidative stress in HCV-infected liver[7]. In addition to the oncogenic factors, the microenvironment is also an important factor as the soil for initiation and progression of HCC. Budhu et al[8] reported that metastasis of HCC was associated with an immune system in the liver, suggesting that liver tissues surrounding tumors have an effect on prognosis of HCC.

Macrophages, one of the predominant infiltrating cell types into the tumor[9], are attracted by chemokines[10]. When Mφs are activated, they can eliminate malignant cells or draw out reactions causing tissue destruction[11]. Although the significant role of macrophage colony-stimulating factors (M-CSF) and tumor-infiltrating Mφs in IM of HCC was already reported by Budhu et al[8], the postoperative prognostic significance has not been cleared. Results from the most recent report suggest expression of M-CSF was associated with poor survival after curative liver resection in patients with HCC, emphasizing the important role of the microenvironment in the intrahepatic recurrence of HCC[12]. M-CSF can also induce production of Th2 cytokines[12,13] and some growth factors by the monocyte, which are essential for cell growth and invasion of tumor[14]. Indeed, M-CSF induces vascular endothelial growth factor (VEGF) production and angiogenesis in monocytes. Furthermore, suppression of M-CSF decreased the infiltration of Mφs and suppressed tumor progression. On the other hand, hyper expression of M-CSF or treatment of recombinant M-CSF enhanced infiltration of Mφs, which is associated with growth of tumor cells and angiogenesis[15-17].

Based on these results, it was hypothesized that M-CSF expression in non-tumoral liver tissues may enhance recruitment of M2Mφ and angiogenesis, and enhance growth of tumor cells. This may increase the rate of recurrence of HCC, leading to a poor overall survival. Furthermore, in this study, the role of M-CSF on production of VEGF by the hepatic Mφs and the proliferation of vascular endothelial cells (VEC) were investigated in vitro.
From July 2000 to June 2008, consecutive patients in the University of Yamanashi Hospital (Yamanashi, Japan) who (1) were diagnosed as having HCC and (2) underwent curative resection surgery, were enrolled in this study.

**MATERIALS AND METHODS**

**Patients**

This is a retrospective single-center, open-label study. From July 2000 to June 2008, consecutive patients in the University of Yamanashi Hospital (Yamanashi, Japan) who (1) were diagnosed as having HCC and (2) underwent curative resection surgery were enrolled in this study (Table 1).

**Follow-up and postoperative treatment**

All patients were observed until December 2013. The presence and identification of the hepatitis virus was determined by one or more of the following techniques: (1) the presence of anti-HCV and anti-HBV reactive serum proteins; (2) reverse transcription-PCR for serum HCV-RNA; or (3) the branched DNA-HCV probe assay. Following liver resection patients returned to the ambulatory care clinic for additional tests monthly. Serum α-fetoprotein levels were measured every month. In addition, ultrasonography and computed tomography (CT) of the liver were performed every 2 and 4 mo, respectively. Informed consent was obtained from all subjects who participated in the study, and the study was approved by the Institutional Board on Ethics for Human Science at the University of Yamanashi. All available clinical data for the patients enrolled in this study are summarized in Table 1. Overall survival (OS) was defined as the interval between the dates of surgery and death. Disease-free survival (DFS) was defined as the interval between the dates of surgery and recurrence; if recurrence was not diagnosed, patients were censored on the date of death or the last follow-up. Animals

For the in vitro study, male C57BL/6 mice (8-10 wk of age, obtained from Jackson Laboratories, Bar Harbor, ME), were housed in a clean, temperature-controlled environment with a 12-h light-dark cycle and were given free access to regular laboratory chow diet and water for several days. All animals received humane care, and the study protocols were approved by the Committee of Laboratory Animals at University of Yamanashi according to institutional guidelines.

**Liver tissues**

Sections of tumor and surrounding liver tissues were collected at the time of the operation. Then, sections were fixed in formalin (10%), dehydrated in absolute ethanol and embedded in paraffin. Serial sections (5 μm thick) were prepared for further immunohistochemical analysis.

**Immunohistochemical detection of M-CSF, CD68, CD163, and CD31**

Paraffin-embedded serial sections of liver tissues were stained immunohistochemically with anti-M-CSF (Santa Cruz Biotechnology, Santa Cruz, CA), anti-CD68 (DAKO, Kyoto, Japan), anti-CD163 (Abcam, Cambridge, United Kingdom), or anti-CD31 (Abcam) antibodies. Briefly, after deparaffinization and rehydration, the antigen retrieval procedure was applied by heating the slides in 0.1 mol/L citrate buffer (pH 6.0) for 10 min. The sections were then incubated first with 0.3% H2O2 in distilled water for 5 min to block endogenous peroxidase and then incubated with one of the following antibodies: monoclonal mouse antihuman CD68 (diluted to 1:200), CD163 (diluted to 1:200), CD31 (diluted to 1:200), and M-CSF (diluted to 1:100) at 4°C overnight. Biotinylated secondary antibody conjugated with avidin-biotin horseradish peroxidase (Dako Environ kit/HRP; Dako, Kyoto, Japan) and 3',3'-diaminobenzidine tetrahydrochloride were used for standard avidin biotinylated peroxidase detection. Quantitation of cells that stained positive for CD68, CD163, CD31, and M-CSF was performed using image analysis software (Scion Image; Scion Corp., Frederick, MD) by evaluating five different fields (magnification: × 400) for areas positively stained and expressed as a percentage of the total area.

**Effects of M-CSF on production of vascular endothelial growth factor by the isolated Kupffer cells and the monocytes from mice in vitro**

Kupffer cells were isolated by countercflow centrifugal elution as described in our previous work with some modifications[19]. Briefly, nonparenchymal cells were isolated by collagenase digestion and differential centrifugation using Nycodenz (Nycomed Pharma AS, Oslo, Norway) as described elsewhere[19]. Furthermore, the peripheral blood monocytes were isolated by the centrifugation method using magnetic beads EasySep (Tokyo, Japan). These cells were incubated in media containing recombinant mouse M-CSF (100 ng/mL) (Sigma) for a designated time period (from 1 to 5 d). In another set of experiments, isolated KCs

---

**Table 1  Clinicopathological features of the patients**

| Clinicopathological features | Patients | n = 77 |
|-----------------------------|---------|-------|
| Gender                      |         | male : female = 38 : 10 |
| Age (yr)                    |         | mean = 66.6 (44-85) |
| Virus infection             |         | HCV : HBV : NBNC = 72 : 4 : 1 |
| UICC-TNM classification     |         | Ⅰ : Ⅱ : ⅢA : ⅢB = 41 : 32 : 3 : 1 |
| Tumor number                |         | single : multiple : unknown = 48 : 28 : 1 |
| Tumor size (cm)             |         | mean = 3.0 (1.0-9.5) |
| Portal vein invasion        |         | yes : no : unknown = 7 : 68 : 2 |
| Tumor differentiation       |         | well : mod : poor : unknown = 18 : 44 : 13 : 2 |
| Number of platelet (× 10^9) |         | mean = 50.9 (16-207) |
| Alanine aminotransferase    |         | mean = 13.4 (3.8-28.1) |
| Prothrombin activity (%)    |         | mean = 389.6 (1.8-602.6) |
| Total bilirubin (mg/dL)     |         | mean = 50.9 (0.3-1.9) |
| Total protein (g/L)         |         | mean = 77.1 (33.0-104.0) |
| Indocyanine green R15 (%)   |         | mean = 19.1 (6.0-44.4) |
| Alpha-fetoprotein (ng/mL)   |         | mean = 13.4 (2.9-19.6) |

From July 2000 to June 2008, consecutive patients in the University of Yamanashi Hospital (Yamanashi, Japan) who (1) were diagnosed as having HCC and (2) underwent curative resection surgery, were enrolled in this study.
A proportional hazard model was used to calculate hazard ratio and the \( P \) value of each parameter. \( P < 0.05 \) was considered statistically significant.

**RESULTS**

The clinical characteristics of HCC patients in this study are shown in Table 1. Experiments were performed using resected liver specimens including HCC and tumor free non-cancerous liver tissue by surgery.

**Expression of M-CSF in intratumoral and peritumoral tissues in patients with HCC**

Immunohistochemical staining for M-CSF was performed as described in Patients and Methods section. Immunohistochemical staining for M-CSF was observed in the cytoplasm of both tumor cells and hepatocytes (Figure 1). On the other hand, most of the non-parenchymal cells were negatively stained.

The expression of M-CSF in intratumoral tissues was not correlated with DFS and overall survival rate (OS) (data not shown), consistent with the previous report\(^\text{[11]}\). On the other hand, in peritumoral tissues, DFS and OS were significantly shorter in the high expression group than in the low expression group (Figures 2 and 3), consistent with the previous reports\(^\text{[11]}\).

**Expression of CD68, CD163, and CD31 in liver tissues of patients with HCC**

Immunohistochemical staining for CD68 (a marker of the M1\(\text{M}\phi\)s and/or the monocytes), CD163 (a marker of the M2\(\text{M}\phi\)s), and CD31 (a marker of the vascular
endothelial cells) was performed as described in the Patients and Methods section. A positive correlation was observed between the expression of M-CSF and CD31 in the peritumoral liver tissues, but not between M-CSF and CD163 (Figure 4), or CD68 (data not shown).

To determine the cutoff value of the M-CSF positive area, an ROC curve was drawn using recurrence within one year. Patients with a high expression of CD31 or CD163 in peritumoral tissues showed significantly poorer DFS compared with patients with low expression of these markers (Figures 2 and 3). Furthermore, patients with high expression of CD163 in peritumoral tissues showed significantly poorer OS compared with patients with low expression of these markers. Although positive staining for CD68 was detected in peritumoral tissues, the number of CD68-positive cells was not correlated with DFS (Figure 2) or OS (data not shown).

**Prognostic factors**

According to the ROC curve, the ideal cutoff value of the densities of M-CSF, CD163, and CD31 were 36, 26, and 20, respectively. The median DFS was 12.3 mo for patients with high expression of M-CSF in peritumoral tissues, which was significantly shorter compared with the median DFS for patients with low expression of M-CSF (43.3 mo). Furthermore, the median survival times for the high CD163 density and the low density group were 12.2 and 32.0 mo, respectively. The median survival times for the high CD31 density and the low density group were 13.6 and 37.3 mo, respectively.

**M-CSF density, CD163 index, and CD31 index in peritumoral tissues are predictable factors for prognosis in patients with HCC**

The univariate analysis of the prognostic value for various factors assessed in the present study is shown in Table 2.

In clinicopathologic factors, the size of the tumor, the clinical disease stage, serum ALT and AFP levels are useful to assess recurrence of HCC after surgery. In the present study, there were significant differences in the univariate analysis of DFS between the UICC-TNM Stages (Stage I vs Stages II and III) (Table 2). Furthermore, there were significant differences in the univariate analysis of OS between the tumor number (single vs multiple) and the fibrosis score (1-3 vs 4). In multivariate analysis of the prognostic power, the
fibrosis score was a factor for predicting the length of overall survival in patients with HCC (Table 2).

M-CSF density, CD163 index, and CD31 index in peritumoral liver tissues appear to be risk factors for DFS by univariate analysis (Table 2). When each of these markers was included in the multivariate analysis, M-CSF density and CD163 index were found to be the only significant predictors for DFS. Alternatively, peritumoral M-CSF density, CD163 index, and CD31 index appear to be risk factors for OS by univariate analysis. Furthermore, when each of these markers was included in the multivariate analysis, the CD163 index was found to be the only significant predictor for OS.
Incidence of HCC, including MC recurrence and IM, peritumoral tissues was correlated with a high expression of M-CSF in the present study, the high expression of M-CSF in peritumoral liver tissues (WT) by inhibiting the expression of M2 M-deficient mice (KO) compared with their littermates of chemically-induced HCC was reduced in M-CSF reported from this laboratory that the incidence in peritumoral liver tissues also reported that M-CSF is predominantly detected in tumors and is related with poor survival M-CSF is observed in tumor tissues in various human cancers and is related with poor survival[20-25]. It was also reported that M-CSF is predominantly detected in peritumoral liver tissues[20]. Furthermore, it was reported from this laboratory that the incidence of chemically-induced HCC was reduced in M-CSF deficient mice (KO) compared with their littermates (WT) by inhibiting the expression of M2 M and angiogenesis in peritumor liver tissues[26]. In the present study, the high expression of M-CSF in peritumoral tissues was correlated with a high incidence of HCC, including MC recurrence and IM, and poor prognosis after curative resection (Figures 2 and 4), consistent with the previous report[11]. Thus, M-CSF is involved in hepatic carcinogenesis and its progression. Based on these reports, this study investigated whether M-CSF induces hepatic carcinogenesis, most likely by enhancing angiogenesis by M-CSF-induced hepatic macrophages.

In the present study, expression of M-CSF differed in intratumoral tissues and peritumoral liver tissues, suggesting that the expression level of M-CSF differs in each individual. Importantly, the level of M-CSF expression did not correlate with any pathophysiologic factors. Therefore, the expression of M-CSF may be associated with other genetic factors in each patient[11]. Indeed, Okamoto et al[27] reported that a specific gene profile in non-tumoral tissue predicted MC recurrence or IM of HCC. Alternatively, placental[28,29] and endothelial cells[30] excreted M-CSF under hypoxic conditions. Based on this result, distribution of M-CSF may be caused by hypoxia in hepatocytes due to compression by the primary tumor. A tumor itself also enhances acute and chronic inflammation, causes cytokine production and attracts Mφs to peritumoral liver tissues. The previous study indicated that implanted or spontaneous tumors induced vascular endothelial growth factor in peritumoral tissue that was much greater than in the intratumoral tissue[31]. Furthermore, angiogenesis was greater in peritumoral tissues than in the intratumoral tissues in chemically-induced HCC in mice[26]. Taken together, the expression of M-CSF in peritumoral hepatocytes may be associated with the genetic heterogeneity in each individual or inflammatory factors in the liver.

**Production of VEGF by isolated Kupffer cells and monocytes from mice**

The production of VEGF by isolated KCs increased in a dose- and time-dependent manner after incubation with M-CSF in media (Figure 5). Furthermore, the production by isolated monocytes also increased in a time dependent manner by stimulation with M-CSF (Figure 5). Although the production of VEGF increased in both isolated KCs and monocytes incubated with M-CSF, production was significantly greater in the KC compared with the monocytes (Figure 5).

**Proliferation of isolated vascular endothelial cells isolated**

Cell proliferation of isolated VECs markedly increased in cells treated with M-CSF compared with those that were not treated with M-CSF in media (Figure 6). Importantly, among the groups studied, the proliferation was greatest in the M-CSF-treated VECs co-cultured with the KCs.

**DISCUSSION**

**M-CSF is involved in progression of hepatocellular carcinoma after curative resection**

It was previously reported that overexpression of M-CSF is observed in tumor tissues in various human cancers and is related with poor survival[20-25]. It was also reported that M-CSF is predominantly detected in peritumoral liver tissues[20]. Furthermore, it was reported from this laboratory that the incidence of chemically-induced HCC was reduced in M-CSF deficient mice (KO) compared with their littermates (WT) by inhibiting the expression of M2 M and angiogenesis in peritumor liver tissues[26]. In the present study, the high expression of M-CSF in peritumoral tissues was correlated with a high incidence of HCC, including MC recurrence and IM, and poor prognosis after curative resection (Figures 2 and 4), consistent with the previous report[11]. Thus, M-CSF is involved in hepatic carcinogenesis and its progression. Based on these reports, this study investigated whether M-CSF induces hepatic carcinogenesis, most likely by enhancing angiogenesis by M-CSF-induced hepatic macrophages.

In the present study, expression of M-CSF differed in intratumoral tissues and peritumoral liver tissues, suggesting that the expression level of M-CSF differs in each individual. Importantly, the level of M-CSF expression did not correlate with any pathophysiologic factors. Therefore, the expression of M-CSF may be associated with other genetic factors in each patient[11]. Indeed, Okamoto et al[27] reported that a specific gene profile in non-tumoral tissue predicted MC recurrence or IM of HCC. Alternatively, placental[28,29] and endothelial cells[30] excreted M-CSF under hypoxic conditions. Based on this result, distribution of M-CSF may be caused by hypoxia in hepatocytes due to compression by the primary tumor. A tumor itself also enhances acute and chronic inflammation, causes cytokine production and attracts Mφs to peritumoral liver tissues. The previous study indicated that implanted or spontaneous tumors induced vascular endothelial growth factor in peritumoral tissue that was much greater than in the intratumoral tissue[31]. Furthermore, angiogenesis was greater in peritumoral tissues than in the intratumoral tissues in chemically-induced HCC in mice[26]. Taken together, the expression of M-CSF in peritumoral hepatocytes may be associated with the genetic heterogeneity in each individual or inflammatory factors in the liver.

**Role of the hepatic microenvironment in initiation and progression of HCC**

The high rate of IM and MC recurrence after complete resection indicated that the non-tumoral hepatic

### Table 2  Univariate and Multivariate analyses of factors associated with recurrence and survival

| Factors                     | Univariate |         |         |         | Multivariate |         |         |         |
|-----------------------------|------------|---------|---------|---------|--------------|---------|---------|---------|
| Age: 60 yr vs < 60 yr       | 0.240      |         |         |         | 0.023        |         |         |         |
| Gender: female vs male      | 0.760      |         |         |         | 0.111        |         |         |         |
| Indx of α-SMA: ≥ 12 vs < 12 | 0.751      |         |         |         | 0.432        |         |         |         |
| Indx of CD163: ≥ 26 vs ≤ 26 | < 0.001    | 4.517   | 1.879-10.857 | 0.001  | < 0.001      | 1.086   | 1.039-1.135 | < 0.001 |
| M-CSF density: ≥ 36 vs ≤ 36 | < 0.001    | 4.826   | 2.045-11.389 | < 0.001 | 0.037        |         |         |         |
| Indx of CD31: ≥ 20 vs < 20  | 0.002      |         |         |         | 0.020        |         |         |         |
| MφF: ≥ 100 μm < 100         | 0.232      |         |         |         | 0.785        |         |         |         |
| AFP-L3%: ≥ 20 vs < 20       | 0.827      |         |         |         | 0.909        |         |         |         |
| PIVKA-II: ≥ 100 μm < 100    | 0.841      |         |         |         | 0.325        |         |         |         |
| Tumor size: ≥ 2 cm vs < 2 cm| 0.185      |         |         |         | 0.847        |         |         |         |
| Tumor number: multiple vs single | 0.447 |         |         |         | 0.038        |         |         |         |
| Tumor differentiation:      | 0.379      |         |         |         | 0.745        |         |         |         |
| well vs mod. vs poor        | 0.755      |         |         |         | 0.015        |         | 0.002   |         |
| Fibrosis score: 1, 2, 3 vs 4| 0.020      |         |         |         | 0.173        |         |         |         |
| TNM stage: I vs II vs IIIa  |            |         |         |         |             |         |         |         |

Tables are shown univariate and multivariate analysis of prognostic markers associated with the disease-free and the overall survival.
The peritumoral microenvironment plays a key role in tumor initiation and progression. Previous investigations of causes of HCC were mainly focused on factors of tumor initiation as “seeds.” On the other hand, few studies that focus on hepatic microenvironmental factors as “soil” were reported. Indeed, Ezaki et al. reported that the hyperexpression of thymidine phosphorylase in the peritumoral liver tissues was correlated with the higher incidence of postoperative recurrence of HCC. Furthermore, Yu et al. reported that vascular density was higher in peritumoral tissues compared with that in intratumoral tissue, leading to increased expression of VEGF and hypoxia inducible factor-1 in peritumoral liver tissues. Moreover, it was reported that immunological features in the peritumoral tissue predicted venous metastases in HCC. In this study, the high density of M-CSF in peritumoral liver tissues was correlated with a high incidence of HCC and prognosis, consistent with the previous report (Figures 2 and 3). Taken together, it is concluded that the peritumoral microenvironment, as “the soil,” is also important in understanding the mechanism of incidence of HCC. Furthermore, previous studies and this study suggest that postoperative adjuvant therapies could target not only the subclinical carcinoma cells, but also the microenvironment in the liver.

**Role of M-CSF induced macrophage in the progression of HCC**

The union of M-CSF expression, population of M2Mφs and angiogenesis in peritumoral tissues had a better predictable power for prognosis in HCC (Figures 2 and 3, and Table 2). The number of Mφs was greater in peritumoral tissue than in intratumoral tissue, consistent with results in previous reported studies. In the present study, expression of M-CSF, M2Mφs and angiogenesis in the peritumoral liver tissue was correlated with DFS after surgery (Figure 2). The role of microenvironments in intratumoral tissues and
peritumoral tissues may be different in initiation and progression of HCC. Expression of M-CSF, CD31 and M2Mφs in intratumoral tissues may be involved in promoting the dissemination of the cancer cells\cite{37-39}. M-CSF and M2Mφs in the peritumoral tissues are involved in accelerating colonization and growth of disseminated tumor cells, leading to micrometastasis, since M-CSF and M2 Mφ in the tumor is eliminated by operation. Therefore, as the defense to inhibit growth of the tumor, the peritumoral liver tissue, which supplies M-CSF to the tumor\cite{31}, plays a pivotal role by providing a fruitful soil for micrometastasis of HCC as "seeds". The role of the Mφs in providing a fertile soil as the metastasis niche has also been reported\cite{40}. In this study, the number of M2Mφs in the peritumoral tissues was correlated with the expression of M-CSF in the peritumoral tissues and was linked with DFS and OS (Figures 2 and 3). Thus, M-CSF-induced M2Mφs may be involved in DFS. In addition to this result, the number of M2Mφs and the expression of angiogenic factors were also positively correlated. Importantly, VEGF production by isolated hepatic Mφ was increased by M-CSF stimulation (Figure 5) and proliferation of isolated VEC was greatest in the cells incubated with M-CSF-stimulated hepatic Mφ in the presence of M-CSF in media (Figure 6). Thus, M-CSF-induced M2Mφs could be involved in progression of HCC by inducing angiogenesis.

**Clinical applications and conclusion**

Undoubtedly, M-CSF and M2Mφ could be suitable targets for adjuvant therapy after surgery, since in the present study the expression of M-CSF and the number of M2Mφs increased in the peritumoral tissues, hepatic Mφs incubated with M-CSF in media produced VEGF, and the proliferation was greatest in the M-CSF-treated VECs co-cultured with the KCs among the groups studied. Thus, this study indicates that M-CSF expressed in the peritumoral liver tissue could predict the recurrence of patients with HCC after surgery and also indicates that the remnant liver may play an important role in recurrence and metastasis. Therefore, evaluation of M-CSF is a useful result that can be easily assessed in specimens collected during surgery.

**COMMENTS**

### Background

Expression of macrophage colony-stimulating factor (M-CSF) was associated...
Kono H et al. Role of M-CSF in hepatic carcinogenesis

with hepatocellular carcinoma (HCC) progression, disease recurrence, and poor survival after hepatectomy, highlighting the importance of the peritumoral tissue environment in the intrahepatic recurrence of HCC.

Research frontiers
In this study, the authors investigated the relationship between the M-CSF-matured hepatic macrophage and the prognosis of HCC after resection.

Innovations and breakthroughs
In this manuscript, the major point is that vascular endothelial growth factor derived from the M-CSF-matured hepatic macrophage plays a pivotal role in the prognosis of HCC.

Applications
M-CSF or its receptor could be a new molecular target for therapy against HCC.

Terminology
The present study indicates that M-CSF expressed in peritumoral liver tissues can predict recurrence in patients with HCC after surgery and also implies that the remnant liver may play a key role in recurrence and metastasis. Therefore, evaluation of M-CSF is a useful result that can be easily assessed in specimens collected during liver tumor resection.

Peer-review
In this paper, the authors aimed at investigating the role of M-CSF in patients with HCC after resection. They analyze the prognostic value of M-CSF, CD163, CD31 and other clinicopathologic parameters for patients’ disease-free survival (DFS) with HCC and find M-CSF in non-cancer tissues can act as a predictor for patients DFS after resection.

REFERENCES
1 Inoue H, Seitz HK. Viruses and alcohol in the pathogenesis of primary hepatic carcinoma. Eur J Cancer Prev 2001; 10: 107-110 [PMID: 11263585 DOI: 10.1097/00008469-200102000-00016]
2 Kountouras J, Lygidakis NJ. New epidemiological data on liver oncogenesis. Hepatogastroenterology 2000; 47: 855-861 [PMID: 10919047]
3 Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN, Liu H, Xia JL, Wu ZQ, Fan J, Ma ZC, Zhou XD, Lin ZY, Liu KD. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 187-196 [PMID: 14685850 DOI: 10.1007/s00432-003-0511-1]
4 Wiktor-Jedrzejczak W, Gordon S. Cytokine regulation of the macrophage (M phi) system studied using the colony stimulating factor-1-deficient op/op mouse. Physiol Rev 1996; 76: 927-947 [PMID: 8874489]
5 Koike K, Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatol Res 2006; 34: 65-73 [PMID: 16364681 DOI: 10.1016/j.hepres.2005.11.001]
6 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917 [PMID: 14667750 DOI: 10.1016/S0140-6736(03)14964-1]
7 Maki A, Kono H, Gupta M, Asakawa M, Suzuki T, Matsuda M, Fujii H, Rusyn I. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol 2007; 14: 1182-1190 [PMID: 17195915 DOI: 10.1245/s10434-006-9049-1]
8 Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammla US, Chen Y, Qin LX, Tang ZY, Wang XW. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 99-111 [PMID: 16904609 DOI: 10.1016/j.ccr.2006.06.016]
9 Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13: 265-270 [PMID: 1388654 DOI: 10.1016/0167-5699(92)90008-U]
10 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545 [PMID: 11229684 DOI: 10.1016/S0140-6736(00)09406-0]
11 Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008; 26: 2707-2716 [PMID: 18509183 DOI: 10.1200/JCO.2007.15.6211]
12 Verreck FA, de Boer T, Langenboom DG, Hoeve MA, Kramer M, Vaisberg E, Kastelein R, Koik A, de Waal-Malef'y R, Ottenhoff TH. Human IL-12-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 2004; 101: 4560-4565 [PMID: 1507057 DOI: 10.1073/pnas.0400981101]
13 Smith W, Feldmann M, Londë M. Human macrophages induced in vitro by macrophage colony-stimulating factor are deficient in IL-12 production. Eur J Immunol 1998; 28: 2498-2507 [PMID: 9710227 DOI: 10.1002/(SICI)1521-4141(199808)28:8<2498::AID-EJIM111>3.0.CO;2-5]
14 Zins K, Abraham D, Soud M, Aharinejad S. Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 2007; 67: 1038-1045 [PMID: 17283136 DOI: 10.1158/0008-5472.CAN-06-2295]
15 Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007; 67: 5064-5066 [PMID: 17545560 DOI: 10.1158/0008-5472.CAN-07-0912]
16 Sica A, Schiappà T, Mantovani A, Allavena P. Tumor-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 717-727 [PMID: 16520032 DOI: 10.1016/j.ejca.2006.01.003]
17 Paulus P, Stanley ER, Schäfer R, Abraham D, Aharinejad S. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res 2006; 66: 4349-4356 [PMID: 16618760 DOI: 10.1158/0008-5472.CAN-05-3523]
18 Kono H, Fuji H, Asakawa M, Yamamoto M, Maki A, Matsuda M, Rusyn I, Matsumoto Y. Functional heterogeneity of the kupffer cell population is involved in the mechanism of gadolinium chloride in rats administered endotoxin. J Surg Res 2002; 106: 179-187 [PMID: 12127824 DOI: 10.1006/jsrc.2002.6434]
19 Kono H, Enomoto N, Connor HD, Wheeler MD, Bradford BU, Rivera CA, Kadisaka MB, Mason RP, Thurman RG. Medium-chain triglycerides inhibit free radical formation and TNF-alpha production in rats given enteral ethanol. Am J Physiol Gastrointest Liver Physiol 2000; 278: G467-G476 [PMID: 10712267]
20 Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med 1995; 27: 79-85 [PMID: 7742005 DOI: 10.3109/078538995090331941]
21 Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78 [PMID: 14708027 DOI: 10.1038/nrc1256]
22 Smith HO, Anderson PS, Kuo DY, Goldberg GL, DeVictoria CL, Boocock CA, Jones JG, Runowicz CD, Stanley ER, Pollard JW. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Clin Cancer Res 1995; 1: 313-325 [PMID: 9815987]
23 Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, Okulczyk B, Kedra B, Laszewicz W, Dubrowski A, Szmitkowski M. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta 2007; 380: 208-212 [PMID: 17368603 DOI: 10.1016/j.cca.2007.02.037]
24 Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, Kedra B, Konopko M, Szmitkowski M. The diagnostic value of G-CSF measurement in the sera of colorectal cancer and adenoma patients. Clin Chim Acta 2006; 371: 143-147 [PMID: 16603145 DOI: 10.1016/j.cca.2006.02.037]
Kono H et al. Role of M-CSF in hepatic carcinogenesis

25 Groblewska M, Mroczko B, Wereszczyńska-Siemiatkowska U, Myśliwiec P, Kedra B, Szmitkowski M. Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. *Clin Chem Lab Med* 2007; **45**: 30-34 [PMID: 17243911 DOI: 10.1515/CCLM.2007.025]

26 Hara M, Kono H, Furuya S, Hirayama K, Tsuchiya M, Fuji H. Macrophage colony-stimulating factor plays a pivotal role in chemically induced hepatocellular carcinoma in mice. *Hepatol Res* 2014; **44**: 798-811 [PMID: 23710613 DOI: 10.1111/hepr.12174]

27 Okamoto M, Utsunomiya T, Wakiyama S, Hashimoto M, Fukazawa K, Ezaki T, Hanai T, Inoue H, Mori M. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. *Ann Surg Oncol* 2006; **13**: 947-954 [PMID: 16788756 DOI: 10.1245/ASO.2006.07.018]

28 Hayashi M, Ohkura T, Inaba N. Elevation of serum macrophage colony-stimulating factor before the clinical manifestations of preeclampsia. *Am J Obstet Gynecol* 2003; **189**: 1356-1360 [PMID: 14634568 DOI: 10.1067/mob.2003.43504]

29 Hayashi M, Ohkura T, Inaba N. Increased levels of serum macrophage colony-stimulating factor before the onset of preeclampsia. *Horm Metab Res* 2003; **35**: 588-592 [PMID: 14605992 DOI: 10.1055/s-2003-43504]

30 Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. *J Interferon Cytokine Res* 1999; **19**: 91-104 [PMID: 10090394 DOI: 10.1089/107990999314234]

31 Fukumura D, Xavier R, Sugiuira T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksi T, Jain RK, Seed B. Tumor induction of VEGF promoter activity in stromal cells. *Cell* 1998; **94**: 715-725 [PMID: 9753319 DOI: 10.1016/S0092-8674(00)01731-6]

32 Ezaki T, Ikegami T, Ishida T, Aimitsu S, Mori M, Fujihara M. Significance of thymidine phosphorylase in HCC with chronic liver disease for long-term postoperative recurrence. *J Surg Oncol* 2003; **83**: 173-19; discussion 179 [PMID: 12827687 DOI: 10.1002/jso.10259]

33 Ezaki T, Ikegami T, Maeda T, Yamada T, Ishida T, Hashizume M, Mihara Y. Prognostic value of thymidine phosphorylase activity in liver tissue adjacent to hepatocellular carcinoma. *Int J Clin Oncol* 2005; **10**: 171-176 [PMID: 15996964 DOI: 10.1007/s10147-005-0488-7]

34 Yu D, Zhuang L, Sun X, Chen J, Yao Y, Meng K, Ding Y. Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma. *BMC Cancer* 2007; **7**: 122 [PMID: 17680955 DOI: 10.1186/1471-2407-7-122]

35 Liu K, He X, Lei XZ, Zhao LS, Tang H, Liu L, Lei BJ. Pathomorphological study on location and distribution of Kupffer cells in hepatocellular carcinoma. *World J Gastroenterol* 2003; **9**: 1946-1949 [PMID: 12970881 DOI: 10.3748/wjg.v9.i9.1946]

36 Cervello M, Foderà D, Florena AM, Soresi M, Tripodo C, D’Alessandro N, Montalto G. Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. *World J Gastroenterol* 2005; **11**: 4638-4643 [PMID: 16094702 DOI: 10.3748/wjg.v11.i30.4638]

37 Mehlen P, Puisieux A. Metastasis: a question of life or death. *Nat Rev Cancer* 2006; **6**: 449-458 [PMID: 16723991 DOI: 10.1038/nrc1886]

38 Bockhorn M, Jain RK, Munn LL. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? *Lancet Oncol* 2007; **8**: 444-448 [PMID: 17466902 DOI: 10.1016/S1470-2045(07)70140-7]

39 Gupta GP, Massague J. Cancer metastasis: building a framework. *Cell* 2006; **127**: 679-695 [PMID: 17110329 DOI: 10.1016/j.cell.2006.11.001]

40 Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerss NA, Zha Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. *Nature* 2005; **438**: 820-827 [PMID: 16341007 DOI: 10.1038/nature04186]
